{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:49:13Z","timestamp":1788461353152,"version":"build-2803163510"},"reference-count":42,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,11]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Efgartigimod alfa is an important novel drug for the treatment of myasthenia gravis. However, postmarketing safety data for this drug is limited, underscoring the need for comprehensive safety evaluations in real-world populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>This study aims to identify adverse event (AE) signals associated with efgartigimod alfa using the Food and Drug Administration Adverse Event Reporting System (FAERS) database, with a focus on evaluating unexpected AEs not previously observed in clinical trials. AE reports with efgartigimod alfa as the primary suspect from the first quarter of 2022 to the fourth quarter of 2023 were extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Signal strength was assessed using Reporting Odds Ratio, Proportional Reporting Ratio, Empirical Bayes Geometric Mean and Bayesian Confidence Propagation Neural Network methods at the Preferred Term level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1403 valid cases were retrieved. Urinary tract infection was the most reported AE, while procedural headache demonstrated the strongest signal across all four algorithms. Sepsis, atrial fibrillation and transient ischaemic attack were significant unexpected AEs. The median onset time for AEs was 57.00\u2009days, with cumulative incidence of AEs reaching 37.31% at 30 days and 64.25% at 100 days post-treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analysis of real-world data from the FAERS database revealed that most significant AEs were consistent with clinical trials, but some unexpected AEs were additionally identified, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-095652","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T03:45:34Z","timestamp":1752464734000},"page":"e095652","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03770403","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yaxin","family":"Ju","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8219-1018","authenticated-orcid":false,"given":"Xiaohong","family":"Qin","sequence":"additional","affiliation":[{"name":"Sichuan Provincial Center for Mental Health, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"},{"name":"Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"2025121407150812000_15.7.e095652.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"2025121407150812000_15.7.e095652.2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025121407150812000_15.7.e095652.3","first-page":"865","article-title":"Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025121407150812000_15.7.e095652.4","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","article-title":"Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management","volume":"19","author":"Vanoli","year":"2022","journal-title":"Neurotherapeutics"},{"key":"2025121407150812000_15.7.e095652.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03019.x"},{"key":"2025121407150812000_15.7.e095652.6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/1744-9987.12474","article-title":"Therapeutic Apheresis in Hematologic, Autoimmune and Dermatologic Diseases With Immunologic Origin","volume":"20","author":"Bambauer","year":"2016","journal-title":"Ther Apher Dial"},{"key":"2025121407150812000_15.7.e095652.7","first-page":"341","article-title":"Efgartigimod: First Approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025121407150812000_15.7.e095652.8","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11136-016-1435-y","article-title":"Health-related quality of life associated with systemic corticosteroids","volume":"26","author":"Sullivan","year":"2017","journal-title":"Qual Life Res"},{"key":"2025121407150812000_15.7.e095652.9","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacc\u00e0","year":"2023","journal-title":"J Neurol"},{"key":"2025121407150812000_15.7.e095652.10","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"2025121407150812000_15.7.e095652.11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/2168479013514236","article-title":"A Review of Statistical Methods for Safety Surveillance","volume":"48","author":"Huang","year":"2014","journal-title":"Ther Innov Regul Sci"},{"key":"2025121407150812000_15.7.e095652.12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s43441-024-00705-7","article-title":"A Clustering Ensemble Method for Drug Safety Signal Detection in Post-Marketing Surveillance","volume":"59","author":"Chakraborty","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"2025121407150812000_15.7.e095652.13","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"2025121407150812000_15.7.e095652.14","doi-asserted-by":"publisher","DOI":"10.2165\/11599740-000000000-00000"},{"key":"2025121407150812000_15.7.e095652.15","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1407418","article-title":"Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients","volume":"15","author":"Wang","year":"2024","journal-title":"Front Neurol"},{"key":"2025121407150812000_15.7.e095652.16","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061214","article-title":"Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control","volume":"12","author":"Konno","year":"2024","journal-title":"Biomedicines"},{"key":"2025121407150812000_15.7.e095652.17","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70391","article-title":"Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real-World Cohort of 77 Patients","volume":"31","author":"Hao","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"2025121407150812000_15.7.e095652.18","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"2025121407150812000_15.7.e095652.19","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis","volume":"271","author":"Li","year":"2024","journal-title":"J Neurol"},{"key":"2025121407150812000_15.7.e095652.20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401218"},{"key":"2025121407150812000_15.7.e095652.21","doi-asserted-by":"publisher","DOI":"10.1172\/jci97911"},{"key":"2025121407150812000_15.7.e095652.22","first-page":"277","article-title":"Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases","volume":"6","author":"Kobrynski","year":"2012","journal-title":"Biologics"},{"key":"2025121407150812000_15.7.e095652.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.06.001"},{"key":"2025121407150812000_15.7.e095652.24","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9"},{"key":"2025121407150812000_15.7.e095652.25","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Front Neurol"},{"key":"2025121407150812000_15.7.e095652.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.05.002"},{"key":"2025121407150812000_15.7.e095652.27","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.28744"},{"key":"2025121407150812000_15.7.e095652.28","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.44"},{"key":"2025121407150812000_15.7.e095652.29","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"2025121407150812000_15.7.e095652.30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","article-title":"Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids","volume":"30","author":"Tannemaat","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2025121407150812000_15.7.e095652.31","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27974"},{"key":"2025121407150812000_15.7.e095652.32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis","volume":"55","author":"Guptill","year":"2022","journal-title":"Autoimmunity"},{"key":"2025121407150812000_15.7.e095652.33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.28003","article-title":"Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events","volume":"69","author":"Singer","year":"2024","journal-title":"Muscle Nerve"},{"key":"2025121407150812000_15.7.e095652.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.004"},{"key":"2025121407150812000_15.7.e095652.35","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center","volume":"31","author":"Frangiamore","year":"2024","journal-title":"Eur J Neurol"},{"key":"2025121407150812000_15.7.e095652.36","first-page":"e2661","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2025121407150812000_15.7.e095652.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-020-01549-z","article-title":"Gender differences in quality of life among patients with myasthenia gravis in China","volume":"18","author":"Dong","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2025121407150812000_15.7.e095652.38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025121407150812000_15.7.e095652.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10891-1"},{"key":"2025121407150812000_15.7.e095652.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-020-01802-4","article-title":"Prospective study of stress, depression and personality in myasthenia gravis relapses","volume":"20","author":"Bogdan","year":"2020","journal-title":"BMC Neurol"},{"key":"2025121407150812000_15.7.e095652.41","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00415-021-10759-4","article-title":"Long-term outcome in patients with myasthenia gravis: one decade longitudinal study","volume":"269","author":"Bozovic","year":"2022","journal-title":"J Neurol"},{"key":"2025121407150812000_15.7.e095652.42","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients","volume":"45","author":"Di Stefano","year":"2024","journal-title":"Neurol Sci"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-095652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:15:20Z","timestamp":1765725320000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-095652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,13]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2024-095652"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095652","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}